Holen Sie sich die Stockscreener-App
4.77
6.24%
0.28
Handel nachbörslich:
4.76
-0.010
-0.21%
Whitehawk Therapeutics Inc Aktie (WHWK) Neueste Nachrichten
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise - Stocktwits
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesTrade Idea Marketplace - Newser
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7 - Moomoo
WHWK News | WHITEHAWK THERAPEUTICS INC (NASDAQ:WHWK) - ChartMill
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for CPT113 Linker-Payload Technology and Advances Clinical Programs - Minichart
Whitehawk expands ADC pipeline with Hangzhou DAC option deal - Investing.com UK
Whitehawk Expands CPT113 ADC Platform Through New Option Deal - TipRanks
Whitehawk Therapeutics expands ADC pipeline with option for CPT113 across up to five programs - TradingView
Whitehawk Therapeutics (WHWK) Climbs +3.69% — Resistance at $4.43 in Focus 2026-05-20Option Breadth - Newser
Cancer treatment developer Whitehawk joins TD Cowen oncology summit - Stock Titan
Acuta Capital boosts Whitehawk (WHWK) stake to about 9% after PIPE - Stock Titan
Whitehawk Therapeutics (WHWK) CMO receives 19,132-share stock grant at $3.92 - Stock Titan
Whitehawk Therapeutics (WHWK) executive awarded 51,020 shares in Form 4 filing - Stock Titan
Whitehawk Therapeutics (WHWK) CFO receives 38,265-share stock award - Stock Titan
Whitehawk Therapeutics (WHWK) CEO awarded 51,021 shares in new stock grant - Stock Titan
Whitehawk Therapeutics (WHWK) director gains stock grant and large pre-funded warrant - Stock Titan
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - marketscreener.com
WHWK PE Ratio & Valuation, Is WHWK Overvalued - Intellectia AI
WHWK SEC FilingsWhitehawk Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Whitehawk Therapeutics, Inc.Common Stock (NQ: WHWK - The Chronicle-Journal
Whitehawk Therapeutics: 'Hold' On Name Change, Next Generation PTK7 ADC Targeting (WHWK) - Seeking Alpha
Avoro boosts Whitehawk Therapeutics (WHWK) stake with pre-funded PIPE warrants - Stock Titan
Avoro Capital Advisors boosts Whitehawk (NASDAQ: WHWK) stake with 6.38M pre-funded warrants - Stock Titan
JonesTrading Initiates Whitehawk Therapeutics(WHWK.US) With Buy Rating, Announces Target Price $7 - Moomoo
May 2026's Promising Penny Stocks - simplywall.st
Wilson Sonsini Advises Whitehawk Therapeutics on $87.5 Million PIPE Financing - Wilson Sonsini
Whitehawk Therapeutics Raises $87.5M in Private Placement to Advance Antibody Drug Conjugate Cancer Pipeline - Minichart
Whitehawk Therapeutics announces $87.5m private placement equity financing - marketscreener.com
Whitehawk Therapeutics raises $87.5m in private placement By Investing.com - Investing.com Australia
Whitehawk Therapeutics Raises $87.5M PIPE Financing to Advance ADC Cancer Pipeline - citybiz
Whitehawk Therapeutics Announces $87.5 Million PIPE Financing - TipRanks
Whitehawk Therapeutics raises $87.5m in private placement - Investing.com
Whitehawk Therapeutics Raises $87.5 Million in PIPE, Selling Stock and Pre-Funded Warrants - TradingView
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing - TradingView
Whitehawk (Nasdaq: WHWK) prices $87.5M PIPE to fund ADC pipeline - Stock Titan
Number of shareholders of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Number of shareholders of Whitehawk Therapeutics, Inc. – FWB:3350 - TradingView
Whitehawk Therapeutics, Inc. announced that it expects to receive $87.499998 million in funding from Coastlands Capital LP, QVT Financial LP, Avoro Capital Advisors LLC, Invus Financial Advisors, LLC, The Invus Group, LLC - marketscreener.com
Natural gas mineral firm WhiteHawk reveals sevenfold revenue surge in US IPO filing - Reuters
Whitehawk Therapeutics stock rating reaffirmed at Citizens on ADC progress By Investing.com - Investing.com Canada
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Oppenheimer Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Whitehawk Therapeutics (NASDAQ: WHWK) posts Q1 2026 loss as ADC focus ramps - Stock Titan
Whitehawk (Nasdaq: WHWK) posts Q1 loss with cash runway into 2028 - Stock Titan
WHITEHAWK THERAPEUTICS ($WHWK) Releases Q1 2026 Earnings - Quiver Quantitative
Whitehawk Therapeutics Q1 net loss beats estimates - TradingView
Cancer drug developer Whitehawk says $123M can fund operations into 2028 - Stock Titan
The sustainable advantages Whitehawk Therapeutics (WHWK) is developing (Eye on Rally) 2026-05-05Social Flow Trades - newser.com
Whitehawk Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Whitehawk Therapeutics (WHWK) price target increased by 10.29% to 6.38 - MSN
WHWK Whitehawk Therapeutics reports far wider than expected Q4 2025 loss, with shares edging 0.5% lower today.Revenue Breakdown Analysis - Newser
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest Update - MarketBeat
Whitehawk Therapeutics (WHWK) price target increased by 13.33% to 5.78 - MSN
[ARS] Whitehawk Therapeutics, Inc. SEC Filing - Stock Titan
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):